Holen Sie sich die Stockscreener-App
2.21
5.96%
-0.14
Vorhandelsmarkt:
2.21
Schlusskurs vom Vortag:
$2.35
Offen:
$2.25
24-Stunden-Volumen:
753.21K
Relative Volume:
1.67
Marktkapitalisierung:
$62.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-0.5525
EPS:
-4
Netto-Cashflow:
$-21.66M
1W Leistung:
-8.30%
1M Leistung:
-12.99%
6M Leistung:
-39.45%
1J Leistung:
+82.64%
1-Tages-Spanne:
$2.11
$2.25
1-Wochen-Bereich:
$2.11
$2.51
52-Wochen-Spanne:
$1.15
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Firmenname
Nrx Pharmaceuticals Inc
Sektor
Branche
Telefon
484-254-6134
Adresse
1201 ORANGE STREET, WILMINGTON
Vergleichen Sie NRXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.21 | 66.03M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-02 | Eingeleitet | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRx Eyes Faster Commercial Path as NRX-101 Moves Into TMS-Enhanced Depression Treatment - MyChesCo
NRx’s Preservative-Free Ketamine Reaches FDA Review as Company Targets 2026 Launch - MyChesCo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Cash from financing activities of NRX Pharmaceuticals, Inc. – HAM:B1Q - TradingView
Is NRx Pharmaceuticals Inc. stock a bargain at current levelsMarket Rally & Weekly Top Stock Performers List - Newser
BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals amends IND filing for NRX-101 to include use for TMS - MSN
Is NRx Pharmaceuticals Inc. Equity Warrant stock cheap compared to fundamentalsMarket Weekly Review & Verified Chart Pattern Trade Signals - Newser
NRXP Analyst Maintains Buy Rating with $34 Target | NRXP Stock N - GuruFocus
NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - NewMediaWire
NRx Pharmaceuticals (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - Digital Journal
NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - The Globe and Mail
NRx Pharmaceuticals to Discuss New NRX-101 Pipeline Indication for Augmentation of Transcranial Magnetic Stimulation - citybiz
Nrx Pharmaceuticals Inc amends IND filing for NRX-101 to include TMS use - marketscreener.com
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation - Investing News Network
NRx Pharmaceuticals Amends Investigational New Drug Filing for NRX-101 to Include Use with Transcranial Magnetic Stimulation in Treatment of Depression - Quiver Quantitative
BTIG Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial ... - Enidnews.com
NRx Pharmaceuticals to discuss new NRX-101 pipeline - GlobeNewswire
D. Boral Capital Maintains NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq
Market Wrap: What momentum indicators show for NRx Pharmaceuticals Inc. stock2025 Valuation Update & Precise Trade Entry Recommendations - BỘ NỘI VỤ
NRx Pharmaceuticals (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date - Digital Journal
NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date - NewMediaWire
NRXP: Analyst Maintains 'Buy' Rating with $34 Target Price | NRX - GuruFocus
FDA Submission for Abbreviated New Drug Application; $750 - openPR.com
NRx Pharmaceuticals Announces US Food and Drug Administration Receipt of ANDA for KETAFREE, a Preservative-Free IV KetamineNRx Pharmaceuticals - citybiz
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine - The Manila Times
Nrx Pharmaceuticals announces US Food and Drug Administration (FDA) receipt of ANDA for Ketafree - marketscreener.com
Nrx Pharmaceuticals Announces Us Food And Drug Administration (FDA) Receipt Of ANDA For Ketafree - TradingView
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call - The Manila Times
NRx Pharmaceuticals (NASDAQ: NRXP) plans Dec. 2, 9:00am ET corporate update call - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at NobleCon21 - MSN
NRx Pharmaceuticals (NRXP) to Present at NobleCon21 - NewMediaWire
NRx Pharmaceuticals and HOPE Therapeutics to Present at NobleCon21Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference - citybiz
NRx Pharmaceuticals to Present at NobleCon21 on Advances in Psychiatric Treatments and Drug Development - Quiver Quantitative
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference - marketscreener.com
NRx Pharmaceuticals (NASDAQ: NRXP) to outline revenue and pipeline progress at NobleCon21 - Stock Titan
What Macro Trends Could Affect Ruchira Papers Limiteds OutlookStock Valuation Metrics & Free Discover Breakout Stocks Early - earlytimes.in
Is NRx Pharmaceuticals Inc. stock a buy in volatile marketsMarket Activity Summary & Reliable Price Breakout Alerts - BỘ NỘI VỤ
NRx Pushes Fast-Track Depression Treatments as Losses Mount and Clinics Expand - MSN
Why NRx Pharmaceuticals Inc. Equity Warrant stock attracts global investorsWeekly Trade Report & Expert Curated Trade Setup Alerts - moha.gov.vn
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA) (PR Newswire) - Aktiellt
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products (PR Newswire) - Aktiellt
NRx Pharmaceuticals appoints Weinberg as new auditor, dismisses Salberg By Investing.com - Investing.com Canada
NRx Pharmaceuticals appoints Weinberg as new auditor, dismisses Salberg - Investing.com
[8-K] NRX Pharmaceuticals, Inc. Reports Material Event | NRXP SEC FilingForm 8-K - Stock Titan
Will NRx Pharmaceuticals Inc. stock pay special dividendsMarket Performance Recap & Technical Pattern Alert System - BỘ NỘI VỤ
Finanzdaten der Nrx Pharmaceuticals Inc-Aktie (NRXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):